Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1148130-18-0

Post Buying Request

1148130-18-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1148130-18-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1148130-18-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,8,1,3 and 0 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1148130-18:
(9*1)+(8*1)+(7*4)+(6*8)+(5*1)+(4*3)+(3*0)+(2*1)+(1*8)=120
120 % 10 = 0
So 1148130-18-0 is a valid CAS Registry Number.

1148130-18-0Relevant articles and documents

Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma

Yamada, Ken,Brousseau, Margaret,Honma, Wataru,Iimura, Akiko,Imase, Hidetomo,Iwaki, Yuki,Kawanami, Toshio,Lasala, Daniel,Liang, Guiqing,Mitani, Hironobu,Nonomura, Kazuhiko,Ohmori, Osamu,Pan, Meihui,Rigel, Dean F.,Umemura, Ichiro,Yasoshima, Kayo,Zhu, Guoming,Mogi, Muneto

, p. 8466 - 8481 (2017/11/03)

Herein we describe the discovery and characterization of a novel, piperidine-based inhibitor of cholesteryl ester transfer protein (CETP) with a core structure distinct from other reported CETP inhibitors. A versatile synthesis starting from 4-methoxypyridine enabled an efficient exploration of the SAR, giving a lead molecule with potent CETP inhibition in human plasma. The subsequent optimization focused on improvement of pharmacokinetics and mitigation of off-target liabilities, such as CYP inhibition, whose improvement correlated with increased lipophilic efficiency. The effort led to the identification of an achiral, carboxylic acid-bearing compound 16 (TAP311) with excellent pharmacokinetics in rats and robust efficacy in hamsters. Compared to anacetrapib, the compound showed substantially reduced lipophilicity, had only modest distribution into adipose tissue, and retained potency in hypertriglyceridemic plasma in vitro and in vivo. Furthermore, in contrast to torcetrapib, the compound did not increase aldosterone secretion in human adrenocortical carcinoma cells nor in chronically cannulated rats. On the basis of its preclinical efficacy and safety profile, the compound was advanced into clinical trials.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1148130-18-0